Abstract: Selective expression of a pseudogene of myosin light chain kinase is found in cancer cells and tissues but not in normal cells and tissues. The pseudogene is expressed, and when expressed it inhibits expression of the ancestral myosin light chain kinase. This widespread expression among cancer cell types and the selective expression in cancer cells versus normal cells opens the door to many diagnostic and therapeutic applications.

Abstract: Selective expression of a pseudogene of myosin light chain kinase is found in cancer cells and tissues but not in normal cells and tissues. The pseudogene is expressed, and when expressed it inhibits expression of the ancestral myosin light chain kinase. This widespread expression among cancer cell types and the selective expression in cancer cells versus normal cells opens the door to many diagnostic and therapeutic applications.

Abstract: This invention relates to gene expression and proliferation in eukaryotic, preferably mammalian and most preferably human cells. The invention specifically relates to hypertension associated with proliferation and contractility of vascular smooth muscle cells.

Abstract: Methods of using compounds having certain inhibitory effect to treat cancer are disclosed. More specifically, methods of using myosin light chain kinase inhibitor (MLCK) to treat cancer are disclosed. MLCK inhibitors may cause reduction in MLC-P and induce apoptosis in neoplastic cells and prevent and or inhibit the tumor growth.

Abstract: The present invention relates to a molecular motor actin binding protein, in particular, to Nuclear Myosin I&bgr; (NMI&bgr;) containing a 16 amino acid N-terminal extension involved in transcription. More particularly, this invention is directed to a molecule with oligonucleotide sequence coding for a protein nuclear Myosin I&bgr; (NMI&bgr;) containing a 16 amino acid N-terminal extension that co-localizes with, and forms functional complexes with, RNA polymerase II. This invention is also directed to polyclonal and monoclonal antibodies to the 16 amino acid N-terminal extension that block in vitro RNA synthesis. This invention is also directed to administration to a cell of polyclonal or monoclonal antibodies to the NMI&bgr; 16 amino acid N-terminal extension sequence or to an epitope within that sequence to inhibit transcription. Other inhibitors are also suitable. This invention may be used to treat illness through targeted inhibition of cell proliferation.

Abstract: The present invention relates to a molecular motor actin binding protein, in particular, to Nuclear Myosin I &bgr; (NMI &bgr;) containing a 16 amino acid N-terminal extension involved in transcription. More particularly, this invention is directed to a molecule with oligonucleotide sequence coding for a protein nuclear Myosin I &bgr; (NMI &bgr;) containing a 16 amino acid N-terminal extension that co-localizes with, and forms functional complexes with, RNA polymerase II. This invention is also directed to polyclonal and monoclonal antibodies to the 16 amino acid N-terminal extension that block in vitro RNA synthesis. This invention is also directed to administration to a cell of polyclonal or monoclonal antibodies to the NMI &bgr; 16 amino acid N-terminal extension sequence or to an epitope within that sequence to inhibit transcription. Other inhibitors are also suitable. This invention may be used to treat illness through targeted inhibition of cell proliferation.

Abstract: The present invention relates to a molecular motor actin binding protein, in particular, to Nuclear Myosin I&bgr; (NMI&bgr;) containing a 16 amino acid N-terminal extension involved in transcription. More particularly, this invention is directed to a molecule with oligonucleotide sequence coding for a protein nuclear Myosin I&bgr; (NMI&bgr;) containing a 16 amino acid N-terminal extension that co-localizes with, and forms functional complexes with, RNA polymerase II. This invention is also directed to polyclonal and monoclonal antibodies to the 16 amino acid N-terminal extension that block in vitro RNA synthesis. This invention is also directed to administration to a cell of polyclonal or monoclonal antibodies to the NMI&bgr; 16 amino acid N-terminal extension sequence or to an epitope within that sequence to inhibit transcription. Other inhibitors are also suitable. This invention may be used to treat illness through targeted inhibition of cell proliferation.